- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:10 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 38 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11. | Immunovia AB Q3 Loss Decreases | - | RTTNews | ||
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 26.11. | Immunovia: Strategiewechsel und Aktiensprung nach Q3-Zahlen | 3 | Investing.com Deutsch | ||
| 26.11. | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 108 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| 26.11. | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 118 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen | |
| 03.10. | Immunovia AB: Immunovia publishes information document regarding rights issue | 369 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 01.10. | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 464 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| 29.09. | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 238 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 23.09. | Proteomedix vereinbart Lizenzabkommen mit Immunovia | 1 | punkt4.info | ||
| 22.09. | Onconetix-Tochter lizenziert Biomarker-Technologie an Immunovia | 1 | Investing.com Deutsch | ||
| 22.09. | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 475 | GlobeNewswire (Europe) | CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09. | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 175 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09. | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 188 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09. | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 214 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08. | Immunovia Q2 2025 slides: PancreaSure launch plan unveiled amid stock decline | 3 | Investing.com | ||
| 28.08. | Immunovia-Aktie bricht nach Q2-Zahlen ein - trotz neuem Krebstest | 3 | Investing.com Deutsch | ||
| 28.08. | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 162 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08. | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 408 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08. | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 165 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen | |
| 14.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 261 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 30,050 | -4,24 % | Hims & Hers Health, Inc: Hims & Hers Brings Comprehensive Weight Loss Programme to the UK | Expansion Debuts Hers, Unlocking Personalised Care for British WomenLONDON, Dec. 10, 2025 /PRNewswire/ -- Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive... ► Artikel lesen | |
| BECTON DICKINSON | 166,50 | -0,39 % | BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,390 | -0,86 % | RYMAN HEALTHCARE LIMITED: Ongoing Disclosure Notice for Dean Hamilton | ||
| SOLENO THERAPEUTICS | 41,280 | +1,98 % | BREAKING: Soleno Therapeutics nach Short-Report massiv unter Beschuss | "Der größte reine Biotech-Betrug in den USA gemessen an der Marktkapitalisierung", hat Scorpion Capital vor Kurzem auf der Kurznachrichtenplattform X geschrieben. Der aktivistische Leerverkäufer knöpft... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 12,500 | +1,63 % | Sienna Senior Living Inc: Sienna Senior closes Hygate on Lexington acquisition | ||
| NIAGEN BIOSCIENCE | 5,150 | 0,00 % | Niagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London Conference | Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces... ► Artikel lesen | |
| MICROPORT SCIENTIFIC | 1,090 | +0,93 % | MICROPORT (00853): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE PROPOSED STRATEGIC RESTRUCTURING OF THE CRM BUSINESS | ||
| EXTENDICARE | 13,200 | -2,94 % | Extendicare Inc (2): Extendicare holder Sandpiper holdings decrease to 9.99% | ||
| VERADIGM | 3,600 | 0,00 % | Veradigm Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| NATIONAL HEALTHCARE CORPORATION | 116,00 | -0,85 % | Dividendenbekanntmachungen (30.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1705 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,15 USD 0,1279 EUR AG MORTGAGE INVESTMENT... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 4,260 | -1,39 % | Tigermed Selected as "2025 Forbes China Go-International Flagship Brands" Top 30 | HANGZHOU, China, Nov. 6, 2025 /PRNewswire/ -- Tigermed has been selected as one of the Top 30 companies on the "2025 Forbes China Go-International Flagship Brands" list, Forbes China... ► Artikel lesen | |
| UNIPHAR | 3,415 | 0,00 % | Uniphar PLC - Director/PDMR Shareholding | ||
| AESTHETIC MEDICAL INTERNATIONAL | 0,047 | 0,00 % | Aesthetic Medical International Holdings Group Ltd - 6-K, Report of foreign issuer | ||
| SIEMENS HEALTHINEERS | 44,640 | +0,97 % | Moody's vergibt Investmentgrade-Rating "A3" an Siemens Healthineers | DJ Moody's vergibt Investmentgrade-Rating "A3" an Siemens Healthineers
DOW JONES--Moody's hat Siemens Healthineers die Bonitätsbewertung A3 gegeben, was als sichere Anlage gilt. Der Ausblick ist... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,004 Euro und damit -7,50 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.